504 related articles for article (PubMed ID: 29481970)
1. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
Hirten RP; Iacucci M; Shah S; Ghosh S; Colombel JF
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1374-1384. PubMed ID: 29481970
[TBL] [Abstract][Full Text] [Related]
2. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
3. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
Esse S; Mason KJ; Green AC; Warren RB
JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
[TBL] [Abstract][Full Text] [Related]
4. Medical Therapy for Inflammatory Bowel Disease.
Grevenitis P; Thomas A; Lodhia N
Surg Clin North Am; 2015 Dec; 95(6):1159-82, vi. PubMed ID: 26596920
[TBL] [Abstract][Full Text] [Related]
5. Heading back to the trough (levels of biologics in IBD).
Hanauer SB
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):548-51. PubMed ID: 25311382
[No Abstract] [Full Text] [Related]
6. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
7. Biologic drugs for inflammatory bowel disease.
Yanai S; Matsumoto T
Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment of inflammatory bowel disease: Present status and future perspectives.
Triantafillidis JK; Zografos CG; Konstadoulakis MM; Papalois AE
World J Gastroenterol; 2024 Apr; 30(15):2068-2080. PubMed ID: 38681984
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
11. Biologic response modifiers: Indications, implications, and insights.
Davis BP; Ballas ZK
J Allergy Clin Immunol; 2017 May; 139(5):1445-1456. PubMed ID: 28263774
[TBL] [Abstract][Full Text] [Related]
12. Dual Targeted Therapy for the Management of Inflammatory Bowel Disease.
Haider M; Lashner B
J Clin Gastroenterol; 2021 Sep; 55(8):661-666. PubMed ID: 34238847
[TBL] [Abstract][Full Text] [Related]
13. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
[TBL] [Abstract][Full Text] [Related]
14. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
[TBL] [Abstract][Full Text] [Related]
15. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
[TBL] [Abstract][Full Text] [Related]
16. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
Franceschet I; Cazzagon N; Del Ross T; D'Incà R; Buja A; Floreani A
Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
[TBL] [Abstract][Full Text] [Related]
17. Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease.
Al Draiweesh S; Ma C; Alkhattabi M; McDonald C; Nguyen TM; Beaton M; Chande N; Colquhoun P; Feagan BG; Gregor JC; Khanna R; Marotta P; Ponich T; Quan D; Qumosani K; Sandhu A; Sey M; Skaro A; Teriaky A; Wilson A; Yan B; Brahmania M; Jairath V
Inflamm Bowel Dis; 2020 May; 26(6):949-959. PubMed ID: 31665288
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
19. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.
Ha C; Ullman TA; Siegel CA; Kornbluth A
Clin Gastroenterol Hepatol; 2012 Sep; 10(9):1002-7; quiz e78. PubMed ID: 22343692
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.
Xu Z; Davis HM; Zhou H
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S60-74. PubMed ID: 25707965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
